ECA
TMO icon

Elevate Capital Advisors’s Thermo Fisher Scientific TMO Stock Holding History

Elevate Capital Advisors’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-756
Closed -$438K – 86
2025
Q4 		$438K Sell
756
-59
-7% -$33.4K 0.29% 64
2025
Q3 		$395K Buy
+815
New +$379K 0.28% 61

Other funds holding TMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Elevate Capital Advisors's TMO Position: Q1 2026 in Review

Elevate Capital Advisors sold out of Thermo Fisher Scientific (TMO) in Q1 2026, closing a stake of 756 shares — an estimated $438K sold.

Elevate Capital Advisors first reported a position in TMO in Q3 2025 and held it in 2 quarters. The position peaked at $438K in Q4 2025. 2,594 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Elevate Capital Advisors reported no remaining Thermo Fisher Scientific position as of Q1 2026 after selling out during the quarter.
  • Elevate Capital Advisors sold 756 Thermo Fisher Scientific shares in Q1 2026, an estimated $438K.
  • Elevate Capital Advisors first reported a position in Thermo Fisher Scientific in Q3 2025 and held it in 2 quarters.
  • Elevate Capital Advisors's Thermo Fisher Scientific position peaked at $438K in Q4 2025.
  • 2,594 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Elevate Capital Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.